Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Sr. Director, US Compliance will serve as the lead compliance business partner in support of the company’s planned US commercialization activities for non-small cell lung cancer (NSCLC). The Sr. Director will partner with a range of business functions, serve as a trusted resource for compliance guidance, and ensure launch teams successfully navigate the compliance landscape. This role requires a firm understanding of pharmaceutical best practices and industry requirements, as well as the passion and ability to build relationships with a diverse set of teams all working to revolutionize treatments for patients. This position will report to the VP, US Compliance. This position will be based out of Redwood City, CA on a hybrid basis.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Senior